间充质干细胞治疗缺血性心力衰竭患者：过去、现在和未来。
Mesenchymal Stem Cell Therapy for Patients with Ischemic Heart Failure- Past, Present, and Future.
机构信息
Department of Cardiology, Chui Yang Liu Hospital, Tsinghua University, Beijing 110105, China.
出版信息
Curr Stem Cell Res Ther. 2021;16(5):608-621. doi: 10.2174/1574888X15666200309144906.
The prevalence of Heart Failure (HF) has increased over time. Ischemic heart failure accounts for 50% of HF, which results from ischemic coronary heart diseases such as Myocardial Infarction (MI). Conventionally, reduction of cardiac load and revascularization partially increase cardiomyocyte survival and preserve cardiac functions. Nevertheless, how to improve cardiomyocyte rescue and prevent HF progression remain as challenges. Mesenchymal Stem Cells (MSCs) are multipotent stem cells that give rise to various lineages. The administration of MSCs promotes cardiomyocyte survival and improves cardiac functions in animal models of MI and patients with ischemic cardiomyopathy. However, after injection, MSCs persist for a very short time, indicating that the prolonged protective effects of MSCs on cardiomyocytes may be mediated by paracrine functions of MSCs, such as exosomes. In this review, we focus on MSC-derived exosomes in cardiomyocyte protection to facilitate future applications of exosomes in HF treatment.
心力衰竭（HF）的患病率随着时间的推移而增加。缺血性心力衰竭占 HF 的 50%，由缺血性冠心病如心肌梗死（MI）引起。传统上，减少心脏负荷和血运重建部分增加心肌细胞存活并维持心脏功能。然而，如何改善心肌细胞的抢救和防止 HF 的进展仍然是挑战。间充质干细胞（MSCs）是多能干细胞，可分化为多种谱系。在 MI 动物模型和缺血性心肌病患者中，给予 MSCs 可促进心肌细胞存活并改善心脏功能。然而，注射后，MSCs 只能持续很短的时间，这表明 MSCs 对心肌细胞的长期保护作用可能是由 MSCs 的旁分泌功能介导的，例如外泌体。在这篇综述中，我们重点介绍 MSC 衍生的外泌体在心肌细胞保护中的作用，以促进外泌体在 HF 治疗中的未来应用。
Zotero 插件